188 related articles for article (PubMed ID: 29593879)
1. The Role of Desmopressin in the Management of Severe, Hypovolemic Hyponatremia: A Single-Center, Comparative Analysis.
Ward FL; Tobe SW; Naimark DMJ
Can J Kidney Health Dis; 2018; 5():2054358118761051. PubMed ID: 29593879
[TBL] [Abstract][Full Text] [Related]
2. Use of desmopressin acetate in severe hyponatremia in the intensive care unit.
Rafat C; Schortgen F; Gaudry S; Bertrand F; Miguel-Montanes R; Labbé V; Ricard JD; Hajage D; Dreyfuss D
Clin J Am Soc Nephrol; 2014 Feb; 9(2):229-37. PubMed ID: 24262506
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Desmopressin in Critically Ill Patients with Hyponatremia Requiring 3% Hypertonic Saline.
Tran LK; Marino KK; DeGrado JR; Szumita PM; Dube KM
Am J Med Sci; 2021 Jun; 361(6):711-717. PubMed ID: 33812910
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in Severe Hyponatremia Treated With and Without Desmopressin.
MacMillan TE; Cavalcanti RB
Am J Med; 2018 Mar; 131(3):317.e1-317.e10. PubMed ID: 29061503
[TBL] [Abstract][Full Text] [Related]
5. Desmopressin acetate (DDAVP)-associated hyponatremia and brain damage: a case series.
Achinger SG; Arieff AI; Kalantar-Zadeh K; Ayus JC
Nephrol Dial Transplant; 2014 Dec; 29(12):2310-5. PubMed ID: 25107337
[TBL] [Abstract][Full Text] [Related]
6. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.
Perianayagam A; Sterns RH; Silver SM; Grieff M; Mayo R; Hix J; Kouides R
Clin J Am Soc Nephrol; 2008 Mar; 3(2):331-6. PubMed ID: 18235152
[TBL] [Abstract][Full Text] [Related]
7. Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia.
Sood L; Sterns RH; Hix JK; Silver SM; Chen L
Am J Kidney Dis; 2013 Apr; 61(4):571-8. PubMed ID: 23266328
[TBL] [Abstract][Full Text] [Related]
8. Desmopressin to Prevent Rapid Sodium Correction in Severe Hyponatremia: A Systematic Review.
MacMillan TE; Tang T; Cavalcanti RB
Am J Med; 2015 Dec; 128(12):1362.e15-24. PubMed ID: 26031887
[TBL] [Abstract][Full Text] [Related]
9. DDAVP to prevent rapid correction in hyponatremia.
Goldszmidt MA; Iliescu EA
Clin Nephrol; 2000 Mar; 53(3):226-9. PubMed ID: 10749304
[TBL] [Abstract][Full Text] [Related]
10. Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.
Baek SH; Jo YH; Ahn S; Medina-Liabres K; Oh YK; Lee JB; Kim S
JAMA Intern Med; 2021 Jan; 181(1):81-92. PubMed ID: 33104189
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of proactive versus reactive administration of desmopressin in severe symptomatic hyponatremia: a randomized controlled trial.
Pakchotanon K; Kanjanasuphak N; Chuasuwan A; Gojaseni P; Chittinandana A
Sci Rep; 2024 Mar; 14(1):7487. PubMed ID: 38553491
[TBL] [Abstract][Full Text] [Related]
12. Derivation and Validation of a Novel Risk Score to Predict Overcorrection of Severe Hyponatremia: The Severe Hyponatremia Overcorrection Risk (SHOR) Score.
Woodfine JD; Sood MM; MacMillan TE; Cavalcanti RB; van Walraven C
Clin J Am Soc Nephrol; 2019 Jul; 14(7):975-982. PubMed ID: 31189541
[TBL] [Abstract][Full Text] [Related]
13. The Effect of the Dose of Isotonic Saline on the Correction of Serum Sodium in the Treatment of Hypovolemic Hyponatremia.
Ruiz-Sánchez JG; Meneses D; Álvarez-Escolá C; Cuesta M; Calle-Pascual AL; Runkle I
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33167557
[TBL] [Abstract][Full Text] [Related]
14. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
Verbalis JG; Greenberg A; Burst V; Haymann JP; Johannsson G; Peri A; Poch E; Chiodo JA; Dave J
Am J Med; 2016 May; 129(5):537.e9-537.e23. PubMed ID: 26584969
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a protocol for hypertonic saline administration in acute euvolemic symptomatic hyponatremia: A prospective observational trial.
Bhaskar E; Kumar B; Ramalakshmi S
Indian J Crit Care Med; 2010 Oct; 14(4):170-4. PubMed ID: 21572746
[TBL] [Abstract][Full Text] [Related]
16. The treatment of hyponatremia.
Sterns RH; Nigwekar SU; Hix JK
Semin Nephrol; 2009 May; 29(3):282-99. PubMed ID: 19523575
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
Chatzimavridou-Grigoriadou V; Al-Othman S; Brabant G; Kyriacou A; King J; Blackhall F; Trainer PJ; Higham CE
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4766-e4775. PubMed ID: 33693944
[TBL] [Abstract][Full Text] [Related]
18. Association of intranasal desmopressin therapy with overcorrection of severe hyponatremia: A retrospective, propensity score-based, single-center cohort study.
Jingushi N; Tsuzuki S; Fujii K; Uenishi N; Iwata M; Terasawa T
J Crit Care; 2021 Aug; 64():53-61. PubMed ID: 33794467
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan.
Kim Y; Lee N; Lee KE; Gwak HS
Eur J Clin Pharmacol; 2020 May; 76(5):723-729. PubMed ID: 32055900
[TBL] [Abstract][Full Text] [Related]
20. Patients presenting with severe hypotonic hyponatremia: etiological factors, assessment, and outcomes.
Vu T; Wong R; Hamblin PS; Zajac J; Grossmann M
Hosp Pract (1995); 2009 Dec; 37(1):128-36. PubMed ID: 20877181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
